دورية أكاديمية
أعرض في EDS

Intracavitary adoptive transfer of IL-12 mRNA-engineered tumor-specific CD8 + T cells eradicates peritoneal metastases in mouse models.

التفاصيل البيبلوغرافية
العنوان: Intracavitary adoptive transfer of IL-12 mRNA-engineered tumor-specific CD8 + T cells eradicates peritoneal metastases in mouse models.
المؤلفون: Di Trani CA; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Cirella A; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Arrizabalaga L; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Bella Á; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Fernandez-Sendin M; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Russo-Cabrera JS; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Gomar C; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Olivera I; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Bolaños E; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., González-Gomariz J; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Álvarez M; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Spanish Center for Biomedical Research Network in Oncology (CIBERONC), Madrid, Spain., Etxeberria I; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Palencia B; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Teijeira Á; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Spanish Center for Biomedical Research Network in Oncology (CIBERONC), Madrid, Spain., Melero I; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Spanish Center for Biomedical Research Network in Oncology (CIBERONC), Madrid, Spain.; Department of Immunology and Immunotherapy, Clínica Universidad de Navarra, Pamplona, Spain.; Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain., Berraondo P; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Spanish Center for Biomedical Research Network in Oncology (CIBERONC), Madrid, Spain., Aranda F; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.
المصدر: Oncoimmunology [Oncoimmunology] 2022 Dec 15; Vol. 12 (1), pp. 2147317. Date of Electronic Publication: 2022 Dec 15 (Print Publication: 2023).
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101570526 Publication Model: eCollection Cited Medium: Internet ISSN: 2162-402X (Electronic) Linking ISSN: 21624011 NLM ISO Abbreviation: Oncoimmunology Subsets: MEDLINE
أسماء مطبوعة: Publication: 2015- : Philadelphia, PA : Taylor & Francis
Original Publication: Austin, TX : Landes Bioscience
مواضيع طبية MeSH: CD8-Positive T-Lymphocytes* , Peritoneal Neoplasms*/therapy, Mice ; Animals ; Interleukin-12/genetics ; RNA, Messenger/genetics ; Adoptive Transfer ; Antigens, Neoplasm/genetics ; Disease Models, Animal ; Tumor Microenvironment
مستخلص: Previous studies have shown that local delivery of tumor antigen-specific CD8 + T lymphocytes engineered to transiently express single-chain IL-12 mRNA is highly efficacious. Peritoneal dissemination of cancer is a frequent and often fatal patient condition usually diagnosed when the tumor burden is too large and hence uncontrollable with current treatment options. In this study, we have modeled intracavitary adoptive T cell therapy with OVA-specific OT-I T cells electroporated with IL-12 mRNA to treat B16-OVA and PANC02-OVA tumor spread in the peritoneal cavity. Tumor localization in the omentum and the effects of local T-cell encounter with the tumor antigens were monitored, the gene expression profile evaluated, and the phenotypic reprogramming of several immune subsets was characterized. Intraperitoneal administration of T cells promoted homing to the omentum more effectively than intravenous administration. Transient IL-12 expression was responsible for a favorable reprogramming of the tumor immune microenvironment, longer persistence of transferred T lymphocytes in vivo , and the development of immunity to endogenous antigens following primary tumor eradication. The efficacy of the strategy was at least in part recapitulated with the adoptive transfer of lower affinity transgenic TCR-bearing PMEL-1 T lymphocytes to treat the aggressive intraperitoneally disseminated B16-F10 tumor. Locoregional adoptive transfer of transiently IL-12-armored T cells appears to offer promising therapeutic advantages in terms of anti-tumor efficacy to treat peritoneal carcinomatosis.
Competing Interests: I.M. reports advisory roles with Roche-Genentech, Bristol-Myers Squibb, CYTOMX, Incyte, MedImmune, Tusk, F-Star, Genmab, Molecular Partners, Alligator, Bioncotech, MSD, Merck Serono, Boehringer Ingelheim, Astra Zeneca, Numab, Catalym, and Bayer, and research funding from Roche, BMS, Alligator, and Highlight Therapeutics. MA reports receiving research funding from Highlight Therapeutics and PharmaMar. The rest of the authors have no conflict of interest to declare.
(© 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.)
References: Nucleic Acids Res. 2015 Apr 20;43(7):e47. (PMID: 25605792)
Blood. 2006 Dec 15;108(13):4009-17. (PMID: 16940422)
Bioinformatics. 2013 Jan 1;29(1):15-21. (PMID: 23104886)
J Exp Med. 2003 Aug 18;198(4):569-80. (PMID: 12925674)
Oncoimmunology. 2022 Jul 13;11(1):2098657. (PMID: 35859732)
J Immunol. 2014 Jun 15;192(12):5451-8. (PMID: 24907378)
Int Rev Cell Mol Biol. 2022;370:1-31. (PMID: 35798502)
Mol Ther. 2022 Feb 2;30(2):593-605. (PMID: 34678512)
Int Rev Cell Mol Biol. 2022;371:117-131. (PMID: 35964998)
Br J Cancer. 2019 Jan;120(1):6-15. (PMID: 30413827)
Cancer Cell. 2019 Dec 9;36(6):613-629.e7. (PMID: 31761658)
J Surg Oncol. 2014 Nov;110(6):670-5. (PMID: 24962271)
N Engl J Med. 2016 Dec 29;375(26):2561-9. (PMID: 28029927)
Innovation (Camb). 2021 Jul 01;2(3):100141. (PMID: 34557778)
Int Rev Cell Mol Biol. 2022;368:61-108. (PMID: 35636930)
Blood Cancer J. 2021 Apr 6;11(4):69. (PMID: 33824268)
Lancet Oncol. 2003 May;4(5):277-83. (PMID: 12732164)
Blood. 1997 Oct 1;90(7):2541-8. (PMID: 9326219)
J Exp Med. 2014 Jan 13;211(1):105-20. (PMID: 24367005)
Oncoimmunology. 2020 Oct 7;9(1):1792625. (PMID: 33101771)
Ann Surg Oncol. 2016 Jun;23(6):1971-9. (PMID: 26753751)
Cancers (Basel). 2019 Oct 26;11(11):. (PMID: 31717799)
World J Gastroenterol. 2013 Nov 7;19(41):6979-94. (PMID: 24222942)
J Exp Med. 2019 Jan 7;216(1):176-194. (PMID: 30567719)
Oncoimmunology. 2018 Sep 6;8(1):e1515058. (PMID: 30546956)
Surg Oncol. 2016 Mar;25(1):6-15. (PMID: 26979635)
Bioinformatics. 2014 Aug 1;30(15):2114-20. (PMID: 24695404)
Clin Cancer Res. 2022 May 13;28(10):2038-2049. (PMID: 35046055)
J Transl Med. 2007 Dec 12;5:66. (PMID: 18076766)
J Histochem Cytochem. 2018 Feb;66(2):67-83. (PMID: 29164988)
J Interferon Cytokine Res. 1999 Sep;19(9):1059-66. (PMID: 10505750)
Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12281-6. (PMID: 12213961)
Nat Med. 2011 Oct 30;17(11):1498-503. (PMID: 22037646)
J Immunol. 1988 Mar 1;140(5):1660-4. (PMID: 3126233)
Cell Death Differ. 2015 Feb;22(2):237-46. (PMID: 25190142)
Pharmacol Ther. 2022 Nov;239:108189. (PMID: 35430292)
Cancer Discov. 2021 Nov;11(11):2748-2763. (PMID: 34266984)
Mol Ther. 2011 Apr;19(4):751-9. (PMID: 21285960)
Pancreas. 2013 Jan;42(1):72-5. (PMID: 22850624)
Front Immunol. 2018 Jul 10;9:1593. (PMID: 30042766)
J Immunol. 1998 Jan 1;160(1):395-402. (PMID: 9551996)
J Biol Chem. 2012 Apr 27;287(18):14502-14. (PMID: 22396532)
J Leukoc Biol. 2021 Apr;109(4):717-729. (PMID: 32881077)
Front Immunol. 2021 Mar 18;12:631609. (PMID: 33815381)
Oncoimmunology. 2015 Jan 23;4(3):e994446. (PMID: 25949921)
Expert Opin Drug Discov. 2022 Jan;17(1):41-53. (PMID: 34496689)
Nat Immunol. 2001 May;2(5):397-402. (PMID: 11323692)
J Immunol. 2005 Jan 15;174(2):600-4. (PMID: 15634875)
Oncotarget. 2017 Jun 27;8(26):43481-43490. (PMID: 28415645)
Cancers (Basel). 2021 Feb 25;13(5):. (PMID: 33669017)
Int Rev Cell Mol Biol. 2022;369:107-141. (PMID: 35777862)
Am J Pathol. 2006 Nov;169(5):1739-52. (PMID: 17071597)
Int Rev Cell Mol Biol. 2022;372:207-293. (PMID: 36064265)
J Immunol. 2003 Jun 1;170(11):5398-405. (PMID: 12759414)
Cell. 2019 Sep 5;178(6):1509-1525.e19. (PMID: 31491389)
Eur J Immunol. 2013 Nov;43(11):3051-60. (PMID: 23939911)
Cancer Gene Ther. 2016 May;23(5):142-8. (PMID: 27080226)
Br J Cancer. 2020 Jan;122(1):4-22. (PMID: 31819192)
Trends Immunol. 2017 Jul;38(7):526-536. (PMID: 28579319)
Immunity. 2010 Jan 29;32(1):79-90. (PMID: 20096607)
Cancer Cell. 2021 Jul 12;39(7):973-988.e9. (PMID: 34115989)
J Clin Invest. 2018 Aug 31;128(9):3794-3805. (PMID: 29920191)
Nature. 1996 Jun 13;381(6583):616-20. (PMID: 8637599)
Blood. 2005 Nov 1;106(9):3074-81. (PMID: 15941914)
J Immunol. 2002 Dec 15;169(12):6842-9. (PMID: 12471116)
World J Gastroenterol. 2000 Apr;6(2):169-176. (PMID: 11819552)
Nat Biotechnol. 1997 Jan;15(1):35-40. (PMID: 9035103)
J Exp Med. 2020 Apr 6;217(4):. (PMID: 31951251)
J Exp Med. 1998 Jul 20;188(2):277-86. (PMID: 9670040)
Nat Commun. 2021 Mar 19;12(1):1770. (PMID: 33741914)
Cancer Res. 2011 Sep 1;71(17):5697-706. (PMID: 21742772)
Nat Rev Dis Primers. 2021 Dec 16;7(1):91. (PMID: 34916522)
J Clin Invest. 2011 Dec;121(12):4746-57. (PMID: 22056381)
Proc Natl Acad Sci U S A. 2017 Jul 25;114(30):E6117-E6126. (PMID: 28696283)
World J Gastroenterol. 2014 Oct 21;20(39):14371-80. (PMID: 25339824)
J Transl Med. 2015 Mar 28;13:102. (PMID: 25890361)
Lancet. 1992 Mar 14;339(8794):689. (PMID: 1347391)
Cancer Res. 2007 Jun 15;67(12):5708-16. (PMID: 17575137)
Cancer Res. 2014 Mar 15;74(6):1789-800. (PMID: 24448242)
Vaccines (Basel). 2018 Aug 10;6(3):. (PMID: 30103457)
فهرسة مساهمة: Keywords: Peritoneal carcinomatosis; adoptive cell transfer; interleukin 12; locoregional treatment; mRNA
المشرفين على المادة: 187348-17-0 (Interleukin-12)
0 (RNA, Messenger)
0 (Antigens, Neoplasm)
تواريخ الأحداث: Date Created: 20221219 Date Completed: 20221220 Latest Revision: 20230103
رمز التحديث: 20240829
مُعرف محوري في PubMed: PMC9757485
DOI: 10.1080/2162402X.2022.2147317
PMID: 36531687
قاعدة البيانات: MEDLINE
الوصف
تدمد:2162-402X
DOI:10.1080/2162402X.2022.2147317